Literature DB >> 35896855

Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report.

Paul A G De Klaver1, Carolien M Geesink2, Jasper C A Broen2, Luc J J Derijks3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35896855     DOI： 10.1007/s40261-022-01185-z

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   3.580


× No keyword cloud information.
  11 in total

1.  Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.

Authors:  Sandra Vukusic; Patricia K Coyle; Stephanie Jurgensen; Philippe Truffinet; Myriam Benamor; Salman Afsar; Annie Purvis; Elizabeth M Poole; Christina Chambers
Journal:  Mult Scler       Date:  2019-04-10       Impact factor: 6.312

Review 2.  Pharmacokinetic changes during pregnancy and their clinical relevance.

Authors:  R Loebstein; A Lalkin; G Koren
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 3.  Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications.

Authors:  Torbjörn Tomson; Cecilie Johannessen Landmark; Dina Battino
Journal:  Epilepsia       Date:  2013-01-29       Impact factor: 5.864

4.  Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.

Authors:  Anick Bérard; Jin-Ping Zhao; Irene Shui; Susan Colilla
Journal:  Ann Rheum Dis       Date:  2017-12-08       Impact factor: 19.103

Review 5.  Mechanism of action for leflunomide in rheumatoid arthritis.

Authors:  R I Fox; M L Herrmann; C G Frangou; G M Wahl; R E Morris; V Strand; B J Kirschbaum
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

6.  Birth outcomes in women who have taken leflunomide during pregnancy.

Authors:  Christina D Chambers; Diana L Johnson; Luther K Robinson; Stephen R Braddock; Ronghui Xu; Janina Lopez-Jimenez; Nicole Mirrasoul; Elizabeth Salas; Yunjun J Luo; Shelia Jin; Kenneth Lyons Jones
Journal:  Arthritis Rheum       Date:  2010-05

7.  The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor.

Authors:  Edmond F O'Donnell; Katerine S Saili; Daniel C Koch; Prasad R Kopparapu; David Farrer; William H Bisson; Lijoy K Mathew; Sumitra Sengupta; Nancy I Kerkvliet; Robert L Tanguay; Siva Kumar Kolluri
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

8.  Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.

Authors:  Bernd C Kieseier; Myriam Benamor
Journal:  Neurol Ther       Date:  2014-11-20

9.  Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.

Authors:  A M Hopkins; M D Wiese; S M Proudman; C E O'Doherty; Djr Foster; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-15

Review 10.  A critical review of the reproductive safety of Leflunomide.

Authors:  Birgit Pfaller; Anna Pupco; Tom Leibson; Daniel Aletaha; Shinya Ito
Journal:  Clin Rheumatol       Date:  2019-11-22       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.